$Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study$
QR Code

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study

Abstract Purpose To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma. Patients and Methods This multicenter, non-randomised, phase II study included children with neuroblastoma according...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 50; no. 1; pp. 170 - 177
Main Authors:	Di Giannatale, Angela, Dias-Gastellier, Nathalie, Devos, Annick, Mc Hugh, Kieran, Boubaker, Ariane, Courbon, Frederic, Verschuur, Arnaud, Ducassoul, Stéphane, Malekzadeh, Katty, Casanova, Michela, Amoroso, Loredana, Chastagner, Pascal, Zwaan, Christian M, Munzer, Caroline, Aerts, Isabelle, Landman-Parker, Judith, Riccardi, Riccardo, Le Deley, Marie-Cecile, Geoerger, Birgit, Rubie, Hervé
Format:	Journal Article
Language:	English
Published:	Kidlington Elsevier Ltd 01-01-2014 Elsevier
Subjects:	Adolescent Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Child Child, Preschool Dacarbazine - administration & dosage Dacarbazine - adverse effects Dacarbazine - analogs & derivatives Female Hematology, Oncology and Palliative Medicine Humans Infant Male Medical sciences Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neuroblastoma Neuroblastoma - drug therapy Neuroblastoma - pathology Paediatrics Pharmacology. Drug treatments Phase II Recurrence Temozolomide Topotecan Topotecan - administration & dosage Topotecan - adverse effects Tumors Young Adult Europe Topotecan Phase II Temozolomide Neuroblastoma Paediatrics Antineoplastic agent Relapse Isomerases Cancerology Phase II trial Topoisomerase I inhibitor Child Camptothecin derivatives Human Nervous system diseases Drug combination Treatment resistance Enzyme DNA topoisomerase Enzyme inhibitor Malignant tumor Alkylating agent Treatment Autonomic neuropathy Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Purpose To assess objective response rate (ORR) after two cycles of temozolomide in combination with topotecan (TOTEM) in children with refractory or relapsed neuroblastoma. Patients and Methods This multicenter, non-randomised, phase II study included children with neuroblastoma according to a two-stage Simon design. Eligibility criteria included relapsed or refractory, measurable or metaiodobenzylguanidine (mIBG) evaluable disease, no more than two lines of prior treatment. Temozolomide was administered orally at 150 mg/m2 followed by topotecan at 0.75 mg/m2 intravenously for five consecutive days every 28 days. Tumour response was assessed every two cycles according to International Neuroblastoma Response Criteria (INRC), and reviewed independently. Results Thirty-eight patients were enroled and treated in 15 European centres with a median age of 5.4 years. Partial tumour response after two cycles was observed in 7 out of 38 evaluable patients [ORR 18%, 95% confidence interval (CI) 8–34%]. The best ORR whatever the time of evaluation was 24% (95% CI, 11–40%) with a median response duration of 8.5 months. Tumour control rate (complete response (CR) + partial response (PR) + mixed response (MR) + stable disease (SD)) was 68% (95% CI, 63–90%). The 12-months Progression-Free and Overall Survival were 42% and 58% respectively. Among 213 treatment cycles (median 4, range 1–12 per patient) the most common treatment-related toxicities were haematologic. Grade 3/4 neutropenia occurred in 62% of courses in 89% of patients, grade 3/4 thrombocytopenia in 47% of courses in 71% of patients; three patients (8%) had febrile neutropenia. Conclusion Temozolomide–Topotecan combination results in very encouraging ORR and tumour control in children with heavily pretreated recurrent and refractory neuroblastoma with favourable toxicity profile.
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2013.08.012